New York State Common Retirement Fund lessened its position in Entellus Medical Inc (NASDAQ:ENTL) by 0.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 10,400 shares of the medical technology company’s stock after selling 1 shares during the period. New York State Common Retirement Fund’s holdings in Entellus Medical were worth $172,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Nicholas Company Inc. lifted its stake in shares of Entellus Medical by 1,052.3% in the second quarter. Nicholas Company Inc. now owns 247,685 shares of the medical technology company’s stock worth $4,101,000 after buying an additional 226,190 shares in the last quarter. Nationwide Fund Advisors lifted its stake in shares of Entellus Medical by 61.7% in the second quarter. Nationwide Fund Advisors now owns 6,903 shares of the medical technology company’s stock worth $114,000 after buying an additional 2,635 shares in the last quarter. Granite Point Capital Management L.P. bought a new position in shares of Entellus Medical in the second quarter worth approximately $899,000. TIAA CREF Investment Management LLC lifted its stake in shares of Entellus Medical by 62.0% in the second quarter. TIAA CREF Investment Management LLC now owns 33,328 shares of the medical technology company’s stock worth $552,000 after buying an additional 12,751 shares in the last quarter. Finally, Teachers Advisors LLC lifted its stake in shares of Entellus Medical by 76.5% in the second quarter. Teachers Advisors LLC now owns 21,836 shares of the medical technology company’s stock worth $362,000 after buying an additional 9,467 shares in the last quarter. Hedge funds and other institutional investors own 70.96% of the company’s stock.

ENTL has been the topic of several analyst reports. Zacks Investment Research downgraded shares of Entellus Medical from a “buy” rating to a “hold” rating in a research note on Tuesday, October 31st. Piper Jaffray Companies reiterated a “buy” rating and issued a $21.00 target price on shares of Entellus Medical in a research note on Tuesday, August 22nd. BidaskClub upgraded shares of Entellus Medical from a “hold” rating to a “buy” rating in a research note on Saturday, August 19th. Finally, Canaccord Genuity reiterated a “hold” rating and issued a $17.00 target price on shares of Entellus Medical in a research note on Tuesday, October 17th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $21.17.

In related news, Director Brian E. Farley sold 40,000 shares of the stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $19.78, for a total transaction of $791,200.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Timothy B. Petrick sold 2,000 shares of the stock in a transaction that occurred on Friday, September 22nd. The shares were sold at an average price of $18.00, for a total transaction of $36,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 92,150 shares of company stock worth $1,740,652. 7.70% of the stock is owned by insiders.

Entellus Medical Inc (NASDAQ ENTL) opened at $15.98 on Friday. Entellus Medical Inc has a 52-week low of $11.47 and a 52-week high of $20.34. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.92 and a quick ratio of 1.71.

TRADEMARK VIOLATION NOTICE: “New York State Common Retirement Fund Has $172,000 Stake in Entellus Medical Inc (ENTL)” was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://theolympiareport.com/2017/11/26/new-york-state-common-retirement-fund-has-172000-stake-in-entellus-medical-inc-entl.html.

Entellus Medical Company Profile

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Institutional Ownership by Quarter for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.